Kevin James Craig's most recent trade in ATAI Life Sciences N.V. was a trade of 42,579 Common Stock done at an average price of $4.5 . Disclosure was reported to the exchange on June 25, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.51 per share. | 25 Jun 2026 | 42,579 | 8,437 | - | 4.5 | 192,031 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 25 Jun 2026 | 33,051 | 41,488 | - | 1.5 | 49,577 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 33,051 | 673,808 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 9,528 | 28,608 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 25 Jun 2026 | 9,528 | 51,016 | - | 1.2 | 11,243 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 20 Apr 2026 | 42,579 | 8,437 | - | 5 | 212,895 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 20 Apr 2026 | 27,280 | 35,717 | - | 1.5 | 40,920 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2026 | 27,280 | 706,859 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.84 per share. | 20 Apr 2026 | 15,299 | 51,016 | - | 1.8 | 28,150 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2026 | 15,299 | 372,701 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.55 per share. | 20 Mar 2026 | 100,000 | 8,437 | - | 3.6 | 355,000 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 20 Mar 2026 | 76,224 | 84,661 | - | 1.2 | 89,944 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 76,224 | 38,136 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 20 Mar 2026 | 23,776 | 108,437 | - | 1.5 | 35,664 | Common Stock |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 23,776 | 734,139 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 675,000 | 675,000 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 150,000 | 150,000 | - | - | Restricted Stock Units | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 21 Mar 2025 | 11,563 | 8,437 | - | 1.3 | 15,610 | Common Shares |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 20,000 | 0 | - | - | Restricted Stock Units | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 20,000 | 20,000 | - | - | Common Shares | |
| ATAI Life Sciences N.V. | Kevin James Craig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 757,915 | 757,915 | - | - | Stock Option |